Talimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma

Simple item page
dc.contributor.authorCilento, M.A.
dc.contributor.authorKlein, O.
dc.contributor.authorEgan, E.
dc.contributor.authorRoberts‐Thomson, R.
dc.date.issued2022
dc.description.abstractMerkel cell carcinoma (MCC) is a rare and aggressive cutaneous tumour of neuroendocrine cell origin, which can grow rapidly and metastasise early. Localised disease is treated with surgery and radiotherapy. Disease that reaches a more advanced stage can be treated with a variety of different treatment modalities including surgery, radiotherapy, chemotherapy, radionuclide therapy, immunotherapy, and intralesional therapy. We report a case of a patient who had exhausted all local and systemic treatment options and who subsequently had an exceptional response to intralesional injection of Talimogene laherparepvec (TVEC).
dc.description.statementofresponsibilityMichael A. Cilento, Oliver Klein, Elizabeth Egan, Rachel Roberts-Thomson
dc.identifier.citationAustralasian Journal of Dermatology, 2022; 63(3):e222-e225
dc.identifier.doi10.1111/ajd.13881
dc.identifier.issn0004-8380
dc.identifier.issn1440-0960
dc.identifier.orcidCilento, M.A. [0000-0003-2216-5650]
dc.identifier.urihttps://hdl.handle.net/2440/146192
dc.language.isoen
dc.publisherWiley
dc.rights© 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
dc.source.urihttps://doi.org/10.1111/ajd.13881
dc.subjectcancer intervention; chemotherapy<oncology; dermatology; immunology; skin cancer<oncology
dc.subject.meshHumans
dc.subject.meshHerpesvirus 1, Human
dc.subject.meshCarcinoma, Merkel Cell
dc.subject.meshMelanoma
dc.subject.meshSkin Neoplasms
dc.subject.meshBiological Products
dc.subject.meshTreatment Outcome
dc.subject.meshOncolytic Virotherapy
dc.titleTalimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma
dc.typeJournal article
pubs.publication-statusPublished online

Files

Collections

Research Outputs